Medical condition
Lymphoma
Lymphoma is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- pralatrexate (FOLOTYN) Antineoplastic and immunomodulating agents (L01)
- nelarabine (ATRIANCE) Antineoplastic and immunomodulating agents (L01)
- bexarotene (TARGRETIN) Antineoplastic and immunomodulating agents (L01)
- plerixafor (PLERIXAFOR ARX) Antineoplastic and immunomodulating agents (L03)
- bortezomib (BORTEZOM) Antineoplastic and immunomodulating agents (L01)
- brentuximab vedotin (ADCETRIS) Antineoplastic and immunomodulating agents (L01)
- cytarabine (PFIZER AUSTRALIA PTY LTD) Antineoplastic and immunomodulating agents (L01)
- ibrutinib (IMBRUVICA) Antineoplastic and immunomodulating agents (L01)
- carmustine (GLIADEL) Antineoplastic and immunomodulating agents (L01)
- lenalidomide (LENALIDE) Antineoplastic and immunomodulating agents (L04)
- brigatinib (ALUNBRIG) Antineoplastic and immunomodulating agents (L01)
- romidepsin (ISTODAX) Antineoplastic and immunomodulating agents (L01)
Latest Lymphoma news
Legend Biotech surges on early in vivo CAR-T data for lymphoma
Legend Biotech's experimental in vivo CAR-T therapy, LB2501, reduced or eliminated disease signs in all treated lymphoma patients in a first-in-human trial. The data fuel hopes that the approach could compete with ex vivo therapies like Novartis' Kymriah.
Soligenix HyBryte Phase 3 FLASH2 Trial Shows Interim Results for Cutaneous T-Cell Lymphoma Treatment
Soligenix announces interim efficacy analysis results from Phase 3 FLASH2 trial evaluating HyBryte for cutaneous T-cell lymphoma treatment.
Bispecific Antibody Therapies in B-Cell Lymphomas: FDA Approvals & Market Outlook
This article delves into FDA-approved bispecific antibody therapies for B-cell lymphomas, highlighting key drugs, their mechanisms, and future market trends.
Follicular Lymphoma Clinical Trials Surge: 45+ Companies Developing New Treatments in 2026
DelveInsight reports 45+ companies actively developing follicular lymphoma treatments with 50+ pipeline drugs in clinical trials, signaling major advances ahead.
Abogen's ABO2203 mRNA Cancer Therapy Shows Promise in First-in-Human B-Cell Lymphoma Trial at AACR 2026
Abogen presents preliminary results of ABO2203, an innovative mRNA-encoded bispecific T-cell engager for relapsed/refractory B-cell lymphoma treatment.
FDA Approves Breyanzi: Novel CAR-T Therapy for Mantle Cell Lymphoma
Breyanzi has received FDA approval as a novel CAR-T therapy, providing a promising treatment option for patients with mantle cell lymphoma.